Abstract | Thirty years ago p53 was discovered as a cellular partner of simian virus 40 large T-antigen, the oncoprotein of this tumour virus. The first decade of p53 research saw the cloning of p53 DNA and the realization that p53 is not an oncogene but a tumour suppressor that is very frequently mutated in human cancer. In the second decade of research, the function of p53 was uncovered: it is a transcription factor induced by stress, which can promote cell cycle arrest, apoptosis and senescence. In the third decade after its discovery new functions of this protein were revealed, including the regulation of metabolic pathways and cytokines that are required for embryo implantation. The fourth decade of research may see new p53-based drugs to treat cancer. What is next is anybody's guess.
By now, anybody with an interest in cancer research is already well aware of the existence of p53 and its relevance to practically every aspect of tumour biology 1 . It is impossible to overlook the prominence of p53: with nearly 50,000 PubMed-listed publications so far and a steady flow of new ones entering cyberspace every week, p53 (encoded by TP53) is undoubtedly among the most extensively studied genes and proteins. Every other year hundreds of scientists gather for the International p53 Workshop to discuss this single gene and its protein. However, the idea that p53 is a pivotal tumour suppressor and a mainstay of our body's natural anticancer defence (an idea that is now taken for granted) did not come easily. When it was discovered 30 years ago, p53 was little more than just another interesting protein that most cancer researchers did not consider worthy of much attention, let alone the investment of research time and resources. Unlike 'well-behaved' oncogenes, which were often brought into the spotlight shortly after their discovery, p53 received relatively little attention to begin with. The road leading to p53's eventual rise to prominence and its recognition as the most frequently altered gene in human cancer was long and winding, with concepts being repeatedly revised, extensively modified and sometimes even turned totally upside down. The history of p53 research over the past 30 years provides a rich example of how knowledge evolves in unexpected ways and of how both research 'fashions' and new methodological breakthroughs make us perceive the same facts in radically different ways as time progresses. It also teaches us how extensive delving into aspects of a single gene and its protein can lead to the discovery of new fundamental and general principles that apply to much broader areas of biology and biochemistry.
Prelude: viruses, oncogenes and p53
In the 1970s, much of the attention of cancer researchers focused on cancer-causing viruses. In particular, it became evident that such viruses carried oncogenes. The bigger picture was first resolved for RNA tumour viruses: it was shown that the virus 'hijacks' a cellular gene, which it subsequently reintroduces into the cell that it infects 2 . This leads to the vast overexpression of the encoded cellular protein, sometimes in modified form, and eventually causes transformation. Similarly, oncogenes were uncovered by examining the genes adjacent to the integration sites of retroviruses that resulted in the overexpression of those genes and the formation of tumours in animals.
Over the next 15 years a long list of oncogenes was identified, and it became clear that oncogenes were the cause of cancers in animals. It was therefore not at all far-fetched to expect that DNA tumour viruses might all operate by essentially the same principle: by having picked up oncogenes from the cell or by encoding their own oncogenes. It rapidly became clear that the DNA tumour viruses contained oncogenes not related to the cellular oncogenes of the RNA tumour viruses. But how did these viral oncogenes transform cells and produce tumours in animals? It was proposed that the DNA tumour virus oncogenes encode viral proteins that indirectly lead to the excessive induction of putative cellular oncoproteins. It was from this fertile conceptual soil that p53 first emerged.
Tumours that are induced in experimental animals by small DNA tumour viruses, such as simian virus 40 (SV40), typically express few viral proteins. These proteins are recognized by the immune system of the host, leading to the production of antibodies against them. By the mid 1970s, such antibodies started to gain popularity as tools to identify and monitor proteins encoded by the viral genome and expressed in transformed cells. On the basis of their mode of detection, these proteins were termed viral tumour antigens. Subsequent genetic analysis revealed that the genes encoding these viral tumour antigens were often those also responsible for the transforming activity of the virus, namely the viral oncoproteins. In the case of SV40, the two viral proteins identified in this manner were called large and small T-antigen, respectively.
It was while studying these SV40-derived tumour antigens that, in 1979 (Timeline), several groups independently stumbled on p53. Working at the Imperial Cancer Research Fund (now the London Research Institute), David Lane and Lionel Crawford realized that when sera from animals with SV40-induced tumours were used to immunoprecipitate SV40 large T-antigen, a non-viral protein with an apparent molecular mass of around 53 kDa came along for the ride 3 . Further analysis established that this cellular protein was physically complexed with SV40 large T-antigen. Therefore, the viral protein (which had previously been shown to be Interestingly, Linzer and Levine also found that their antisera precipitated the same 53 kDa protein from teratocarcinoma (a germ cell tumour)-derived cells, despite the fact that these cells did not harbour any SV40 proteins. This indicated that a subset of the antibodies raised against the virusinduced tumour were capable of directly interacting with this cellular protein 4 . In parallel, Lloyd Old and co-workers demonstrated that animals immunized with non-virally transformed cells produced antibodies to the same 53 kDa protein 8 , rightfully qualifying it as a cellular tumour antigen. Moreover, Varda Rotter, working in the laboratory of David Baltimore, was able to identify the same protein as being produced in excess in cells transformed by a retrovirus -the Abelson murine leukaemia virus 9 . Therefore, high levels of this new cellular protein were present not only in SV40-transformed cells but also in other types of cancer cells, although little or none could be detected in non-transformed cells.
As is often the case with independent discoveries of the same protein, each laboratory gave it a different name and continued to publish subsequent papers using their favourite name, creating confusion in this young field. It was only in 1983, during the 1 st International p53 Workshop in Oxted, UK
, that representatives of the different research groups got together to discuss a common nomenclature. After a lot of debate, the term 'p53' emerged as the winner and has stayed with us ever since. Ironically, p53 is actually a misnomer. When coined, it purportedly related to the molecular mass of the protein, which on the basis of its migration in SDS-polyacrylamide gels was estimated to be around 53 kDa. As realized later, this was a gross overestimate, presumably owing to the presence of a proline-rich region that slows down the migration of the protein in such gels. In fact, the correct molecular mass of the human p53 protein is only 43.7 kDa, and that of the mouse protein is even less. But who would dare change a winning name?
the early years: p53 is an oncogene? As outlined above, in 1979 retroviruses were already well known to promote neoplastic transformation by overexpressing 'hijacked' cancer-promoting cellular proteins. In this light, the observation that SV40 drives the overproduction of p53 in transformed cells seemed to logically lead to the conclusion that p53 was also a positive effector of transformation. Notably, a temperaturesensitive mutant of the SV40 large T-antigen gene was found to regulate p53 levels in a temperature-dependent fashion: cellular p53 levels were high when T-antigen was functional but low when T-antigen was non-functional, implying that more p53 means more transformation 10 . In short, p53 looked like a cellular oncogene. Additional findings only seemed to lend further support to this conjecture. For instance, work by Peter Sarnow in the Levine laboratory revealed that the E1B 55 kDa viral tumour antigen encoded by another small DNA tumour virus, adenovirus, also binds p53 and promotes its excessive cellular accumulation 11 . Furthermore, Rotter showed that many tumours produced high levels of p53, whereas this was not observed in normal tissue 12 , lending generality to the early observations of DeLeo and co-workers that transformed, but not non-transformed, cell lines expressed high levels of p53 (Ref. 8) .
With this notion in mind, attempts were then made to experimentally demonstrate the oncogenic properties of p53. Key to this goal was the need to have in hand p53-encoding DNA, so that p53 expression might be specifically manipulated and the biological consequences of such manipulation assessed in vitro and in vivo. Thus started the race to clone p53, which was initiated at roughly the same time in several laboratories. In the early 1980s, gene cloning was not as simple as it is now; in fact, it was a rather tedious trialand-error (mostly error) exercise, calling for a lot of improvisation, ingenuity and (not in the least) good luck. Nevertheless, more than one Timeline | p53: the first 30 years 1979 1983 1984 1988 1989 1990 1991 1992 1993 1994 1997 1998 2000 2001 2002 2003 2004 2005 2007 p53 first cloned 13, 14, [16] [17] [18] 22 p53 first described [3] [4] [5] [6] [7] [8] Oncogenic activities of cloned p53 described [21] [22] [23] [24] [25] • TP53 germline mutations found in Li-Fraumeni syndrome 38, 39 • p53 discovered to induce cell cycle arrest 47, 48 • MDM2 shown to negatively regulate p53
• Trp53-knockout mice shown to be cancer prone 40 • p53 shown to maintain genome stability 139, 140 • p53 gene therapy approved in china 108 • Multiple p53 isoforms described 155 • p53 discovered to have antioxidant function 156 • p53 discovered to regulate metabolism 157, 158 • Determination that p53 is a tumour suppressor [33] [34] [35] • TP53 shown to be mutated or lost in human tumours 36 • CDKN1A (which encodes p21) described as a p53 target gene 71 • p53-MDM2 loop described [87] [88] [89] • MDM2 discovered to drive p53 ubiquitylation and degradation [84] [85] [86] • p73 and p63 described [142] [143] [144] • ArF-p53 connection made 145 • p53 first implicated in senescence 55 • p53 found to be required for embryo implantation 159 • p53-induced senescence shown to prevent cancer 56, 57 • p53 shown to regulate mirNA expression [160] [161] [162] [163] [164] [165] • p53 shown to inhibit the IGF1-mTOr pathway 166 (1984) (1985) (1986) (1987) (1988) ) p53 found to be inactivated in tumour cells [26] [27] [28] [29] p53 found to induce apoptosis 52, 53 Drosophila melanogaster p53 cloned 148, 149 p53 implicated in ageing 152 Murine wild-type p53 sequence validated 30, 31 (1990-1992) p53 shown to be a transcription factor [61] [62] [63] [64] 66 ATM found to phosphorylate p53 (RefS 146, 147) Caenorhabditis elegans p53 cloned 150, 151 p53 found to act on mitochondria to induce apoptosis 153, 154 First p53-DNA complex structure described 141 ATM, ataxia-telangiectasia mutated; IGF1, insulin-like growth factor 1; mirNA, microrNA. www.nature.com/reviews/cancer p e r s p e c t i v e s group overcame these hurdles. In a relatively short stretch of time, several mouse and human p53 cDNA and genomic clones were isolated, validated and reported [13] [14] [15] [16] [17] [18] [19] [20] . Notably, given the low efficiency of the gene cloning protocols available at the time, special efforts were made to identify cells in which the protein of interest was relatively abundant, assuming that the corresponding mRNA was also more abundant in these cells and therefore easier to clone. As p53 is more copious in cancer-derived cells, it was only natural that the first p53 cDNA cloning attempts, including the ones that eventually met with success, used RNA from transformed cells rather than from normal tissue. This fact, the significance of which was appreciated in full only several years later, was largely responsible for the rather unusual course that p53 research took in its first decade.
Using the newly obtained p53 cDNA clones, and acting on the assumption that p53 overexpression contributed to tumorigenic processes, the consequences of such overexpression were next assessed in various experimental model systems. Sure enough, the results fulfilled the expectations. A series of studies by the laboratories of John Jenkins, Moshe Oren, Rotter and Robert Weinberg revealed that transfected p53 could efficiently cooperate with several established oncogenic proteins, most notably HRAS, to transform primary cells in culture, and could facilitate the immortalization of such cells when overexpressed on its own [21] [22] [23] . In these assays, p53 functioned somewhat similarly to the MYC oncoprotein. Furthermore, it could be shown that the cloned p53 augmented the transformed properties of established cell lines 24 and -most notably -could increase the in vivo tumorigenic properties of otherwise p53-null cells 25 . In sum, by the mid 1980s p53 was generally acknowledged as an oncogene, the significance and mechanism of action of which still remained to be uncovered.
p53 revisited: rise of a tumour suppressor The realization that p53 is not actually an oncogene but rather the opposite, namely a tumour suppressor, took several more years. In fact, clues that p53 might be a tumour suppressor had already been around. In retrospect, the first clue was provided by David Wolf and Rotter, who reported in 1984 that Trp53 (which encodes mouse p53) was inactivated by retroviral insertion in an Abelson murine leukaemia virus-transformed mouse cell line 26 . Similar observations were made by Sam Benchimol, Alan Bernstein and co-workers, studying leukaemias induced in mice by the Friend erythroleukaemia virus 27, 28 . Furthermore, Rotter and co-workers showed that TP53 was extensively rearranged and its coding sequences virtually deleted in the human leukaemia-derived cell line HL60, precluding production of p53 (Ref. 29) . The simplest interpretation of these striking observations was that the loss of p53 promotes cancer, implying that sustained p53 function is necessary to prevent cancer. However, the implications of these findings were not apparent at the time. In the face of the seemingly unequivocal evidence for p53 being an oncogene, these were seen as exceptional cases that did not reflect the role of p53 in most common types of cancer. When a group believes something, evidence to the contrary tends to be more readily dismissed.
The cracks in the 'p53 as an oncogene' wall widened when yet another p53 cDNA clone was put to work by Cathy Finlay and Phil Hinds in the Levine laboratory. Surprisingly, this clone was unable to reproduce the transforming effects observed with the earlier clones, even though transformation could be reproduced with a clone obtained from the Oren laboratory. This enigma was solved when they compared the DNA sequences of the various p53 clones they had used, as well as those used in the earlier studies of other groups, and realized that no two clones were identical in sequence. This suggested that at least some if not all of the previously tested clones actually carried mutations in the p53 coding region. This was firmly proved to be the case when the sequence of murine wild-type Trp53, derived from normal tissue, was formally established 30, 31 . It then became clear that p53 mutations are often present in tumour-derived murine cell lines [30] [31] [32] , including the ones used by several laboratories for cDNA cloning, and that only p53 cDNAs carrying such mutations 34, 35 . Together with the earlier observations of loss of p53 in murine tumours and human cancer-derived cells and the subsequent investigation of humans afflicted with Li-Fraumeni syndrome and of Trp53-knockout mice (as discussed below), these data finally firmly established p53 as a bona fide tumour suppressor.
It did not take long to show that TP53 mutations are frequent not only in colorectal cancer but also in most of the common types of human tumours. In at least some types of cancer, TP53 mutations were found to be primarily a late-occurring event, presumably playing a part in progression to advanced, invasive and metastatic disease 36 . An extensive body of data, encompassing thousands of studies, has revealed TP53 mutations in around half of all tumour specimens studied, making it arguably the most frequently mutated gene in human cancers and the most frequently analysed gene in many human tumour specimens. Dedicated p53 databases have been established (for example, see the International Agency for Cancer Research TP53 Mutation Database, The TP53 Website and the p53 Knowledgebase). The first of their kind for a single cancer-related gene, and unprecedented in size, these databases have rapidly become a valuable resource for the p53 research community and for cancer researchers in general. Notably, once it had been figured out that the wild-type p53 protein was a tumour suppressor and that TP53 mutations frequently occurred in cancer cells, the earlier observations that led to the suggestion that p53 is oncogenic could now be explained and placed in the right context. Therefore, it became apparent that all of the studies demonstrating oncogenic activity of p53 had used mutant alleles of Trp53 or TP53, typically derived from a cancer cell line overexpressing that particular mutant. Such mutants can exert cancer-promoting effects, by dominant-negative inactivation of the endogenous wild-type p53, as well as through authentic oncogenic gain-of-function activities (see the Review by Brosh and Rotter, also in this issue 37 ). Therefore, whereas wild-type p53 is a potent tumour suppressor, cancerassociated p53 mutants indeed possess attributes of oncogenes.
For a gene to be unequivocally accepted as a tumour suppressor, two additional criteria are expected to be met: humans carrying germline mutations in that gene should exhibit increased cancer susceptibility, and its loss should confer a cancer-prone phenotype in experimental animal models. Gratifyingly, both criteria were fully met by p53. Indeed, germline TP53 mutations are largely responsible for the devastating hereditary Li-Fraumeni syndrome, characterized by early-onset cancers of diverse types 38, 39 . Furthermore, Trp53-knockout mice, first described by Donehower and co-workers in 1992, develop cancer (mostly lymphomas) with a high penetrance 40 (see the Timeline article by Donehower and Lozano
41
). These results also called for a reinterpretation of how the viral oncogenes of the DNA tumour viruses functioned. It could be shown that the SV40 T-antigen and the adenovirus E1A protein from many different adenovirus serotypes combined with the retinoblastoma protein, RB, and this liberated E2f transcription factors to send the cell into S phase [42] [43] [44] [45] . The small DNA tumour viruses do this to obtain the enzymes and substrates to support their own DNA replication. However, this unusual S phase event is recognized by p53, which then attempts to kill the cell by inducing apoptosis, preventing further viral replication. These viruses counter this move by binding the p53 protein with the large T-antigen or the E1B 55 kDa protein, events that inactivate p53 function just as mutations do in human cancers 46 and that lead to accumulation of inactivated p53 in the transformed cells. Importantly, another group of DNA tumour viruses, the human papillomaviruses (HPVs) (including HPV16 and HPV18, which cause most cervical cancers and are therefore of high clinical relevance) encode two proteins that also target the same cellular proteins: E7, which binds to RB and liberates E2f transcription factors, and E6, which binds p53 and helps to promote its degradation and inactivation 46 . Incidentally, HPV E6 provided the first clue to the importance of the ubiquitin-proteasome pathway in controlling cellular p53 levels 47 . Therefore, in the early part of the last decade of the twentieth century, p53 was recognized as a major tumour suppressor and became a most fashionable gene and protein to study -a fashion that remains today.
How does p53 do it?
With the appreciation of the centrality of p53 in both the life cycle of the DNA tumour viruses and human cancers came the quest to elucidate its mode of action. This quest took two main directions: delineating the biological processes that allow p53 to suppress tumours and elaborating the molecular mechanisms that underlie such processes.
Biological activities of p53. Substantial progress was made when p53 function was reconstituted in transformed cells. This was achieved by various methods, taking advantage of the progress in gene manipulation methodology in the late 1980s and early 1990s. One particularly useful tool was a temperature-sensitive mutant of p53, discovered by accident owing to a misadjusted incubator. This mutant has wild-type p53 activity at 32 o C but loses this activity at 37 o C or above 48 , and through the use of this mutant it was found that reconstitution of wild-type p53 activity can impose growth arrest, both at G1 and G2/M 48 . Similar conclusions were reached using other methodologies [49] [50] [51] . Remarkably, in other types of transformed cells, such as the M1 leukaemia cell line, reactivation of temperature-sensitive p53 had a rather different and striking outcome: within a couple of days, all cells in the culture died. A closer look revealed that this death exhibited typical features of apoptosis 52 . This study, along with similar findings by Shaw and co-workers 53 , established a new role for p53 as a mediator of apoptosis, and provided evidence that apoptosis can serve as a mechanism of tumour suppression. More recently, induction of cellular senescence was identified as an additional mechanism whereby p53 curbs neoplastic processes 54, 55 . This is now emerging as a major mechanism for tumour suppression by p53 (RefS 56, 57) . Overall, the common feature of apoptosis and replicative senescence is that cells undergoing those processes are prevented from giving rise to malignant progeny. Consequently, the induction of either process by p53 in an aspiring cancer cell will prevent that cell from spawning a full-blown tumour. www.nature.com/reviews/cancer p e r s p e c t i v e s Molecular mechanisms behind p53's functions. A huge body of information has been accumulated regarding how p53 works biochemically, which is beyond the scope of this Timeline article. However, the most prominent property of p53 as a protein is its action as a transcription factor. Several seminal studies revealed that p53 possesses a functional transactivation domain 58, 59 (actually, we now know that there are two such domains 60 ) and that it can bind tightly to specific DNA sequences [61] [62] [63] [64] [65] . The ability to bind directly to specific sequences and transactivate nearby genes is the property that distinguishes wild-type p53 from virtually all cancer-associated mutant forms.
These studies provided the first description of a p53 consensus binding sequence, eventually enabling genome-wide computational searches for putative p53 binding sites. Through these and many subsequent studies (for example , p53 was firmly canonized as a sequence-specific transcription factor (see the Review by Resnick and colleagues 70 , also in this issue). Many dozens of p53 target genes have been identified and shown to be transactivated by p53 on its binding to internal or upstream p53 response elements. Many of these genes encode proteins that are intimately involved in apoptosis or in the control of cell cycle progression 70 . This palette of genes provides plausible mechanistic explanations for the ability of activated p53 to promote cell death and/or growth arrest, as realized early on when the genes encoding the cyclin-dependent kinase inhibitor p21 and the pro-apoptotic protein BAX were found to be directly transactivated by p53 (RefS 71, 72) . It is also noteworthy that the first expression microarrays that were used to examine the genes regulated by a specific and inducible (by DNA damage) transcription factor were obtained using p53 for the initiating event 73 . The complexity of the p53 response to different stimuli is still being investigated. The quest to identify additional p53 target genes is steadily ongoing and, as the induction of many of these genes by p53 is turning out to be cell type restricted or context restricted, it is likely that the list is far from being complete. A recent addition to this growing list is microRNAs: many studies have identified several microRNAs, most notably members of the miR-34 family, as being subject to transcriptional regulation by p53 . In parallel, p53 was also found to function as a transcriptional repressor 78 . The mechanisms underlying p53-mediated transcriptional repression are many and diverse, mostly not involving direct binding of p53 to consensus sequences within the gene. The transcriptional activities of p53 imply that it can simultaneously alter the expression of hundreds of genes, thereby explaining how it can exert such profound effects on cell fate.
Notably, p53 was subsequently found to possess non-transcriptional biochemical activities. These are again quite diverse and can be exerted both in the cell nucleus and in the cytoplasm. A detailed account of these additional p53 activities is not in the scope of this article; however, most notable among them is the ability of p53 to interact in the cytoplasm with members of the Bcl2 family of apoptosis-regulatory proteins, thereby directly contributing to mitochondrial outer membrane permeabilization, release of cytochrome c and apoptosis (reviewed in RefS 79, 80) .
p53 and mDm2: in and out of loops A common means to explore the biochemical properties of a protein of interest is by identifying other proteins with which it interacts. This has been performed quite exhaustively for p53, yielding many tens of proven and putative interaction partners. p53 was one of the first mammalian proteins subjected to the then new yeast two-hybrid screen, which yielded a couple of previously unknown p53 interactors that were denoted 53BP1 and 53BP2 for the lack of better functional descriptions 81 . However, probably the most important protein-protein interaction of p53 was discovered in 1992, when MDM2 (previously described as a putative oncoprotein) was shown to bind tightly to p53 and inhibit its biochemical activity 82 . Since then, MDM2 (the human protein is often called HDM2) has emerged as perhaps the key cellular regulator of p53, effectively serving as the p53 gatekeeper. MDM2 can inhibit p53 activity by various means. For example, it can bind to and sterically block the transactivation domain of p53 (Ref. 83) . Moreover, by functioning as a p53-specific E3 ubiquitin ligase it can promote the ubiquitylation and subsequent proteasomal degradation of p53
(RefS 84-86).
A further twist to the p53-MDM2 story came when it was realized that MDM2 is a direct transcriptional target of p53 (RefS 87, 88) . p53 and MDM2 form a negative-feedback loop, in which p53 induces the expression of MDM2, which in turn promotes the degradation of p53 and quenches cellular p53 activity [87] [88] [89] . Extensive work done over the years has taught us that in non-stressed cells p53 function is kept at a low basal state. This is largely achieved through the constant action of the MDM2-p53 loop, which effectively eliminates excessive p53 activity by triggering the production of MDM2. By contrast, in cells exposed to various stress conditions (most notably those that put the cellular genome at risk) p53 is rapidly activated 90 . The first demonstration of the inducible nature of p53 in response to genomic stress was by Warren Maltzman, who showed that ultraviolet irradiation increases cellular p53 concentrations 91 . This, and subsequent pivotal findings by Michael Kastan 92, 93 , led Lane to dub p53 the "guardian of the genome" (Ref. 94 ), a notion that has been strengthened over the years and is believed to represent much of p53's raison d' être in multicellular organisms. The stress-induced switch in p53 levels and activity lies at the heart of p53's performance as a multifaceted, omnipotent tumour suppressor 90 ( fiG. 1) . It is largely MDM2 that guards this switch and ensures that it is not triggered inappropriately. Furthermore, activation of the p53 response in cells experiencing oncogenic stress calls for the disengagement of MDM2 and the abrogation of its inhibitory effects (fiG. 1) , often through a combination of reduced MDM2 levels, reduced MDM2 binding to p53 and reduced E3 activity of MDM2 towards p53, as well as the inhibition of post-ubiquitylation functions of MDM2 in promoting p53 degradation. One illustration of this is the seminal work by Chuck Sherr and co-workers, which revealed that ARF, a tumour suppressor in its own right, largely functions by binding MDM2 and thereby augmenting p53 levels and function 95 . In 1996, MDM2 was joined by a cousin, MDMX (also known as MDM4) 96 . Like MDM2, MDMX binds to the amino-terminal region of p53 and inhibits its activity. Although MDMX does not possess measurable E3 activity, it does contribute to p53 degradation: dimerization with MDMX augments the E3 ligase activity of MDM2 (RefS 97, 98) . Remarkably, inactivation of either MDM2 or MDMX in the mouse results in early embryonic lethality, owing to rampant p53 activation. This dramatic consequence of loss of function of either MDM2 or MDMX can be completely eliminated by concomitant knock out of p53, demonstrating that both MDM2 and MDMX are crucial negative regulators of p53 . In view of the above, it was not surprising to find that excessive expression of MDMX is contributory to human cancer, similar to what had previously been reported for MDM2 (reviewed in Regulation of p53 target genes P rotein-protein interactions
MDM2
of the intricate MDM2-p53 interplay was brought further into focus by the discovery of a single nucleotide polymorphism (SNP) in the human MDM2 gene 103 . Remarkably, individuals carrying a particular MDM2 allele that confers higher expression levels of this gene are predisposed to early-onset cancer, suggesting that subtle differences in basal p53 activity might be enough to affect cancer risk 104 . Although the association of this SNP with cancer has been confirmed by many independent studies, contradictory results have also been reported, particularly with breast cancers 104 . This may stem from the fact that this SNP operates largely in conjunction with the oestrogen receptor (ER) in premenopausal women 105 ; consequently, association studies that do not separate ER + from ER -tumours may greatly underestimate the effect of this SNP.
Not surprisingly, the MDM2-p53 loop has caught the attention of many systems biologists and computational biologists and has since become a favourite model for regulatory interactions within a pathway (for example, see Ref. 106 ). On a more practical level, this loop is being targeted by several promising experimental anticancer drugs (as discussed below). Since the discovery of the MDM2-p53 loop, many additional regulatory loops that involve p53 have been uncovered, and the list is constantly increasing, serving as further testimony to the elaborate networking that p53 is engaged in.
p53 and cancer therapy The centrality of p53 in human cancer makes it a potentially lucrative target for cancer therapy development. Therefore, it is no wonder that many efforts have been undertaken over the years, both in industry and in academia, to develop new p53-based anticancer treatments. This is no simple task: p53 is neither a cell surface protein nor a typical enzyme and so antibodies and low-molecular-mass enzyme inhibitors, which have served as the basis for almost all of the recently developed targeted anticancer therapies, are not pertinent options. Researchers and developers have therefore had to resort to less standard approaches. p53 gene therapy. Early efforts focused largely on various types of gene therapy. The most intuitive strategy was to extend the gene transfer experiments that helped to establish p53 as a tumour suppressor to human cancer patients. Indeed, several organizations took up this approach, and promising data from clinical trials were reported by Introgen Therapeutics, Texas, USA, as early as 1996 (Ref. 107) .
However, completion of these trials and transfer to the clinic were slow to come. Eventually, TP53, delivered with the aid of an adenovirus vector, was approved in 2004 for the treatment of head and neck cancer in China 108 . Although we still have to wait for a critical assessment of the results, it is remarkable that this is the first ever gene therapy protocol approved for routine clinical use in humans. Cancer researchers and patients alike also eagerly await the outcome of crucial Phase III clinical trials with Advexin, the adenovirus p53 gene therapy agent developed originally by Introgen Therapeutics 109 . An alternative gene therapy strategy was developed by McCormick and co-workers at Onyx, California, USA. This again used infection of the tumour with recombinant adenovirus. However, rather than transducing TP53, this virus was deficient in the E1B 55 kDa protein, which binds and inactivates p53. Consequently, this oncolytic virus can replicate in tumour cells that lack functional p53 and kill them, whereas it is incapable of replicating in normal, p53-proficient cells 110 .
Although clinical trials yielded promising results
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, approval for clinical use still needs to be evaluated 112 . In the meantime, a related oncolytic virus, operating on similar principles, has been approved for cancer therapy in China 113, 114 . Only the future will tell whether p53-based gene therapy will indeed be able to make a considerable impact on cancer treatment.
Restoring p53 activity. An entirely different set of strategies has been centred on the development of low-molecular-mass compounds that restore p53 activity in tumour cells. In one approach, such molecules were developed to interact with mutant p53 proteins in tumour cells and thereby alter their conformation and restore their function 115, 116 . The results of clinical trials testing the efficacy of such compounds, exemplified by PRIMA1 (Ref. 115) , are likely to be forthcoming in the next few years. This type of mutant p53-activating drug is potentially applicable in patients with tumours harbouring p53 mutations, comprising in principle around 50% of all cancer patients. The p53-MDM2 feedback loop is the 'heart' of the p53 pathway. Under normal conditions, it maintains constantly low steady-state p53 levels and activity. various stress signals (only a representative subset of p53-activating signals is depicted), related in many ways to carcinogenesis, impinge on this central loop to release p53 from MDM2-mediated inhibition. This increases p53 protein levels and activity, inducing various phenotypic changes. Many p53-activating signals are closely interrelated, as exemplified here for oncogenes, the effect of which on p53 is partly due to their propensity to induce DNA replication stress. The downstream effects of p53 are largely due to its ability to transactivate and repress various subsets of target genes; however, at least in the case of apoptosis, protein-protein interactions (primarily with Bcl2 family members) also have an important role. It is generally believed that the nature of the phenotypic response to p53 activation is, at least partially, proportionate to the amplitude, duration and nature of the activating signal. severe stress induces more extreme, usually irreversible, responses, namely apoptosis and senescence, whereas milder stress leads to a transient growth arrest coupled with an attempt to deal with the cause of stress and repair the damage caused by it. recent evidence indicates that p53 also has an important role in enabling the cell to adjust its metabolism in response to mild normal physiological fluctuations, including those in glucose and other nutrient levels, oxygen availability and reactive oxygen species levels (see the review by vousden and ryan 131 , also in this issue). 
The second approach aims to target the other half of patients, namely those that retain wild-type p53. To this end, efforts have evolved to produce compounds that disrupt MDM2-p53 binding, and so liberate p53 from its inhibitor and enable increased p53 activity. The best documented successful attempt was made by a team at Hoffmann-La Roche in New Jersey, USA; this led to the development of the family of compounds known as Nutlins 117, 118 . Nutlins interact with the p53-binding pocket of the MDM2 molecule, effectively dislodging p53 from MDM2 and leading to extensive p53 activation and induction of a full-blown p53 response, which can trigger tumour shrinkage in experimental animals. A complementary approach led to the identification of the small-molecule inhibitor RITA (reactivation of p53 and induction of tumour cell apoptosis); whereas Nutlins bind to MDM2, RITA binds to p53 and prevents it from being attacked by MDM2 (Ref. 119) . RITA may be particularly promising because, unlike Nutlins, it often has a strong apoptotic effect on tumour cells 120 . It is still too early to tell whether Nutlins, RITA or more recently identified compounds that target the interaction of p53 with MDMX, rather than MDM2 (Ref. 102) , will enter into the clinic. In the meantime, however, these compounds have become popular research tools, serving as a 'clean' means to activate p53 without imposing wide-ranging cellular stress. These types of compounds may be most useful in tumour cells that have amplified and overexpressed MDM2 and therefore inactivated p53. Other compounds leading to the accelerated degradation of MDM2 or the inhibition of MDM2 in cells could also be a promising approach 121 . It is certain that efforts to create new p53-based therapies will be with us for quite some time.
Prognosis. The discovery that p53 has a pivotal role in cell killing by DNA-damaging agents, many of which are in routine use for cancer chemotherapy, gave rise to the expectation that TP53 mutation status would prove to be a reliable predictor of therapy response and patient prognosis. However, these expectations have not yet been fulfilled, probably reflecting the complex genetic nature and extensive diversity of individual tumours, as well as the fact that the p53 pathway is often disarmed in tumours by mechanisms that do not involve direct TP53 mutations. However, there are cases in which TP53 mutations can indeed predict prognosis [122] [123] [124] , and it is likely that the predictive power of TP53 mutation status will increase when tumour subsets are better defined and individual cases more rigorously stratified.
the future What will the next decade of p53 research bring us? Surely we will need to understand what the various isoforms of p53, p63 and p73 (BOX 2) do in both the developing organism and adults. In particular there are already clues that the ratios of some of these isoforms, which can antagonize each other by functioning as either transcriptional activators or repressors, are crucial for cellular function 125 . There is some evidence that the monomers or dimers of p53 can form heterotetramers with p63 or p73 and these three transcription factors can give rise to a combined or new activity, further complicating the possible combinatorics and their functionalities.
To make matters even more complicated, each of these proteins can be extensively modified by phosphorylation, acetylation, methylation, ubiquitylation, sumoylation, neddylation and even addition of N-acetyl glucosamine. This often happens in response to a stress signal or a physiological change in the cell. For that reason we might suspect that these modifications have important functional consequences; however, definitive evidence for what these consequences are is still lacking. For example, the WIP1 phosphatase (also known as PPM1D), which is an oncogene amplified in several cancers, functions upstream of p53 to inactivate the ataxia-telangiectasia mutated (ATM) kinase and prevents p53 phosphorylation by MEK at two specific serine residues [126] [127] [128] . This inactivates the functions of the wild-type p53 protein in a cell, suggesting that these protein modifications are important. Maybe the next 10 years will see a clinical trial with a WIP1 inhibitor that activates p53 in cancers in which WIP1 is amplified.
Although studies in cultured cells have provided a rich body of seemingly impeccable evidence for the pivotal importance of p53 post-translational modifications, many of these conclusions are challenged by data from mutant Trp53 knock-in mice 129 . It is these confusing results that will need to be reconciled over the next 10 years.
Some clarification about these modifications, as well as roles for p53 isoforms, are expected to come from studies that focus on the development of fruit flies, round worms, zebrafish, mice and even humans. In some of these organisms there is growing evidence that p53, p63 and/or p73 have roles in female fertility, female germline genomic stability and reproduction 125 . Over the next 10 years we will surely learn more about this new chapter of p53 family functions. Sexual dimorphism (that is, a role for p63 and p73 in the female germ line but not the male germ line 125 ) of the p53 sisters is partly explained by p53-controlled genes that are also regulated by oestrogen and the ER (for example, MDM2, LIF and WIP1) 105, 126, 130 . There will probably be androgen-regulated genes and perhaps other nuclear receptors and ligands that will be shown to have a role in the p53 pathway in conjunction with diverse kinds of stress.
The next decade should see a more detailed description of the roles of the p53 protein in metabolism (see the Review by Vousden and Ryan 131 , also in this issue), reproduction and fertility, genomic instability in the germ line as well as in cancers, and longevity of the organism (see the Timeline by Donehower and Lozano 41 ) , as well as the use of TP53 mutational spectra to suggest a therapy or predict an outcome Box 2 | the family grows: p63, p73 and isoforms of p53
For a substantial period of time, p53 was believed to be a unique protein, with no obvious relative. This was changed by the discovery of two additional members of the family, p63 and p73 (reviewed in Ref. 132) . Both p63 and p73 have essential roles in development (including that of the skin, the nervous system and female reproductive organs) [133] [134] [135] and can under some circumstances function as tumour suppressors 136, 137 . Curiously, p53, p63 and p73 have closely related DNA-binding domains, bind to similar DNA sequences and can induce the transcription of some of the same genes, but can also induce the transcription of different genes in specific cell types 132 . Furthermore, p53 itself is not a single protein. Over the past few years it has become clear that, through extensive alternative splicing and alternative transcriptional initiation, TP53 produces as many as nine different isoforms, containing various combinations of alternative amino-terminal and carboxy-terminal portions of the protein 138 . Notably, deletion of the N terminus produces a dominant-negative repressor of p53-regulated genes. Some of the p53 isoforms are observed in different tissues and during different stages of development. The precise roles of each of the reported p53 isoforms remain largely unknown. Future unravelling of this story promises to provide both more excitement and more complexity to the ever growing p53 story. 37 , also in this issue). There may even be other diseases, besides cancer, in which p53 could be shown to have a role. Although we can see, and even imagine, the exploration of these areas of research, there are surely other surprises in store for us. If there is one thing we have learnt from the first 30 years of p53 research, it is that something we could not have guessed or thought of will become clear and obvious over the next decade. What we believe today will surely be modified, and this central gene and its protein, its sisters and its ancestors will continue to teach us, challenge us and perplex us well into 2019.
